ReviewCurrent nutrition reports2026
Mechanistic Insights into Houttuynia cordata Thunb. as a Potential Therapeutic Strategy Targeting Metabolic Disorders in Preclinical Models.
Review in Current nutrition reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic syndrome comprises insulin resistance, obesity, hypertension, and dyslipidaemia, increasing the risk of diabetes and cardiovascular diseases. It is a major contributor to global mortality. Approximately 28-31% of the global adult population is affected, with higher prevalence in women (~ 31%) than men (~ 25.7%). Metformin, pioglitazone, and vitamin E are examples of conventional medications that have demonstrated therapeutic advantages, while some patients may experience side effects. This has led to increasing interest in complementary natural compounds that are being studied for their potential efficacy and safety. Houttuynia cordata (H.C), an edible medicinal plant rich in bioactive compounds, has shown potential to regulate lipid metabolism, improve insulin sensitivity, and support hepatic function. This review therefore, focuses on the current preclinical evidence regarding the mechanistic roles of H.C and its bioactive compounds in ameliorating metabolic syndrome and related metabolic abnormalities. MAIN
findingsH.C contains bioactive compounds such as α-pinene, myrcene, β-caryophyllene, limonene, and linalool, which exhibit therapeutic potential. Studies report its extracts (volatile and non-volatile), flavonoids, and phenolics demonstrate anti-hyperglycaemic effects, improve lipid profiles, reduce hepatic lipid accumulation via AMPK activation, and downregulate lipogenic genes. Although generally considered safe as an edible plant, some evidence suggests potential renal toxicity linked to aristolochic acid.
conclusionH.C and its bioactive phytoconstituents have demonstrated promising potential in ameliorating metabolic syndrome in preclinical studies. However, the current evidence supporting the efficacy of H.C extracts in managing metabolic syndrome remains limited. Therefore, further investigations employing well-designed methodologies are essential. Comprehensive research and clinical evaluations are needed to elucidate the precise mechanisms of H.C, which may facilitate its development into an effective therapeutic strategy for the treatment of metabolic syndrome.
Indexed as
Identifiers
42599599What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.